Roche’s Tecentriq With Lurbinectedin Increases Survival From Small-Cell Lung Cancer, Study Says Late-stage trials showed the combination led to a 27% reduction in the risk of death, the company said ...

Tecentriq may be used with the chemotherapy medicines carboplatin and etoposide as their first treatment when their lung cancer: is a type called “extensive-stage small cell lung cancer ...

Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.

Genentech has an extensive development program for Tecentriq, alone and in combination, including multiple ongoing and planned Phase 3 studies across different lung, genitourinary, skin, breast ...

Tecentriq is available as a liquid solution that’s given as an IV infusion (an injection into your vein over a period of time). You’ll receive infusions at your doctor’s office or a clinic.

Key Takeaways Zepzelca plus Tecentriq improved PFS and OS in ES-SCLC patients compared to Tecentriq alone, with a median PFS of 5.4 months versus 2.1 months. The combination therapy showed a median OS ...

For patients with triple-negative breast cancer (TNBC), Tecentriq (atezolizumab) plus neoadjuvant chemotherapy followed by adjuvant Tecentriq did not significantly improve event-free survival (EFS), ...

Tecentriq is approved in the US, EU and countries around the world, either alone or in combination with targeted therapies and/or chemotherapies in various forms of NSCLC, SCLC, certain types of ...

Tecentriq may be used with the chemotherapy medicines carboplatin and etoposide as the first treatment in patients with SCLC when their lung cancer is a type of lung cancer called “extensive ...

Tecentriq cut the risk of disease recurrence or death by 21%, the data showed. For a smaller group of patients whose tumours expressed PD-L1, a protein that helps the cancer hide from the immune ...

Roche said Tecentriq combined with lurbinectedin shows significant survival benefits for patients with extensive-stage small cell lung cancer. The Swiss pharmaceutical company said Tuesday that ...